Ask AI
ProCE Banner Activity

ExpressPoints: The Evolution of Antibody–Drug Conjugates in Breast Cancer

Slideset Download

Download this short summary slideset of key takeaway points from a live presentation on new developments with antibody-drug conjugates in breast cancer.

Released: November 03, 2020

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from

Daiichi Sankyo, Inc.

Faculty Disclosure

Primary Author

Javier Cortes, MD, PhD

Head, Breast Cancer Program
IOB Institute of Oncology
Madrid and Barcelona, Spain

Javier Cortes, MD, PhD: consultant/advisor: Abbvie, AstraZeneca, Bioasis, Biocon, BioInvent, Biontech, Bliss Biopharmaceutical, Boehringer Ingelheim, BridgeBio, Circle Pharma, Clovis Oncology, Daiichi Sankyo, Delcath Systems, Ellipses, Expres2ion Biotechnologies, GEMoaB, Gilead, Hexagon Bio, Hibercell, Jazz, Leuko, Lilly, Menarini, Merck Sharp & Dohme, Reveal Genomics, Roche, Scorpion Therapeutics, Seattle Genetics, Zymeworks; honoraria: AstraZeneca, Daiichi Sankyo, Eisai, Gilead, Lilly, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Stemline, Zuellig; researcher (paid to institution): Ariad, AstraZeneca, Baxalta/Servier Affaires, Bayer Healthcare, Eisai, F. Hoffmann-La Roche, Guardant Health, Iqvia, Merck Sharp & Dohme, Pfizer, Piqur Therapeutics, Roche; individual publicly traded stock/stock options: Leuko; other financial or material support: AstraZeneca, Daiichi Sankyo, Eisai, Gilead, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Stemline; royalties or patent beneficiary: issued patent: Pharmaceutical Combinations of a PI3K Inhibitor and a Microtubule Destabilizing Agent (WO 2014/199294 A), licensed patent: HER2 as a Predictor of Response to Dual HER2 Blockade in the Absence of Cytotoxic Therapy (US 2019/0338368 A1).

Ian Krop, MD, PhD

Professor of Internal Medicine
Associate Cancer Center Director for Clinical Research
Chief Clinical Research Officer
Yale Cancer Center
New Haven, Connecticut

Ian Krop, MD, PhD: consultant/advisor/speaker: ALX Oncology, AstraZeneca, Daiichi Sankyo, EMD Serono, Genentech/Roche, Novartis, Ottimo, Pfizer, Seagen.

Prof Michael Untch, MD, PhD

Director of the Clinic
Gynecology, Gyencologic Oncology and Obstetrics
Helios Hospital Berlin-Buch
Berlin, Germany